Elysium and the quest to bottle the fountain of youth
Alice Lloyd George Contributor Share on Twitter Alice Lloyd George is an early stage investor based in New York and the host of Flux, a series of podcast conversations with leaders in frontier technology. More posts by this contributor One billion 3D views and counting Thomas Reardon and CTRL-Labs are building an API for the brain
In the latest episode of Flux podcast, I sit down with Eric Marcotulli, the co-founder of Elysium, a life sciences company developing consumer-facing health products based on aging research. The company’s first product is Basis, a supplement that combines compounds designed to increase NAD levels and activate sirtuins, boosting cellular health and longevity.
In this conversation we discuss why precursor companies failed, including Cambridge-based Sirtris Pharmaceuticals, which was bought for $720 million in 2008. Eric explains how Elysium is a platform-based company that will sell a host of products and diagnostics, why he believes direct to consumer is the best market strategy, and what the current user base looks like. The company just announced a new clinical trial this week. Eric gets into the importance of bringing academic rigor and peer review
This post was originally published on this site